Recruiting Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC NCT06609876 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +16 more Locations Chinese PLA General hospital — Beijing, None Selected, China View Trial Details
Completed Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery NCT04962958 Conditions Adenocarcinoma, Antimetabolites, Antineoplastic Agents, +13 more Locations Lei Zhang — Guangzhou, Guangdong, China View Trial Details
Completed A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC NCT05262959 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more Locations Zhongshan Hospital, Fudan University, — Shanghai, Shanghai Municipality, China View Trial Details
